Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Trofinetide Published Studies & Presentations
Rett Syndrome
NNZ-2591Published Studies & Presentations
Phelan-McDermid Syndrome
Pitt Hopkins Syndrome
Angelman Syndrome
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2025
2024
2023
2022
2021
2020
2019
2018
Older
Feb 19, 2025
Fast Track granted by FDA for NNZ-2591 in Pitt Hopkins
Feb 07, 2025
Priority Review Voucher sale proceeds received
Feb 07, 2025
Type C Meeting granted by FDA for Phelan-McDermid syndrome
Feb 06, 2025
Neuren to present at autism research meeting
Jan 22, 2025
NEU Presentations at ACMG Annual Clinical Genetics Meeting
Jan 20, 2025
J.P. Morgan Healthcare Conference recap
Jan 16, 2025
Neuren JP Morgan Healthcare Conference 2025 presentation
Jan 15, 2025
Trofinetide marketing application submitted in Europe
1
